Pathologic response prediction to neoadjuvant chemotherapy utilizing pretreatment near-infrared imaging parameters and tumor pathologic criteria

Table 6 Distributions of tumor receptor status and tumor responses based on Miller-Payne grades ^a

	Miller-Payne grades 1 and 2	Miller-Payne grade 3	Miller-Payne grade 4	Miller-Payne grade 5
Triple-negative (n = 6)	n = 1 (17%, 1/6)	n = 1 (17%, 1/6)		n = 4 (67%, 4/6)
ER− HER2+ (n = 6)		n = 1 (16.7%, 1/6)	n = 3 (50%, 3/6)	n = 2 (33.3%, 2/6)
ER+ HER2− (n = 21)	n = 12(57.1%, 12/21)	n = 5(23.8%, 5/21)	n = 2 (9.5%, 2/21)	n = 2 (9.5%, 2/21)
ER− PR + HER2− (n = 1)				n = 1 (100%)
Pretreatment tHb > Th	n = 4 (31%, 4/13)	n = 1 (12.5%, 1/8)	n = 3 (60%, 3/5)	n = 9 (90%, 9/10)
Pretreatment tHb < Th^b	n = 9 (69%, 9/13)	n = 7 (87.5%, 7/8)	n = 2 (40%, 2/5)	n = 1 (10%, 1/10)

^aER, Estrogen receptor; HER2, Human epidermal growth factor receptor 2; tHb, Total hemoglobin. ^bPrediction based on pretreatment tHb. Th is the threshold used to separate responders (> Th = 90 μmol/L) from nonresponders (< Th). This threshold Th was selected in a previously reported study [30].

ISSN: 1465-542X